The effect of drug-injection behavior on genetic evolution of HIV-1

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 1025-1032

  Carneiro, Mariangela ^a,c   Yu, Xiao Fang ^a   Lyles, Cynthia ^a   Templeton, Alan ^b   Weisstein, Anton E ^b   Safaeian, Mahboobeh ^a   Farzadegan, Homayoon ^a   Vlahov, David ^a   Markham, Richard B ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENVELOPE GENE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS MUTATION;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; EVOLUTION, MOLECULAR; FEMALE; GENES, ENV; HIV ANTIBODIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 0033394052     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315044     Document Type: Article

References (43)

1. Brown SM, Stimmel B, Taub RN, Kochwa S, Rosenfield RE. Immunologic dysfunction in heroin addicts. Arch Intern Med 1974;134:1001-6.
2. Wyhran J, Appelboom T, Famaey JH, Govaerts A. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J Immumol 1979;123:1068-70.
3. Orangio OR, Delia Latta P, Marino C, et al. Infections in parenteral drug abusers: further immunologic studies. Am J Surg 1983; 146:738-41.
4. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. Aids 1990;4:869-73.
5. Donahoe RM, Nicholson JK, Madden JJ, et al. Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E-rosette formation and antigenic marker expression. Clin Immunol Immunopathol 1986;41:254-64.
6. Des Jarlais DC, Friedman SR, Marmor M, et al. Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users. AIDS 1987;1:105-11.
7. Galai N, Vlahov D, Margolick JB, Chen K, Graham NM, Munoz A. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:66-74.
8. Margolick JB, Munoz A, Vlahov D, et al. Direct comparison of the relationship between clinical outcome and change in CD4 lymphocytes in human immunodeficiency virus positive homosexual men and injecting drug users. Arch Intern Mel 1994;154:869-75.
9. Prins M, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. Aids 1997; 11:621-31.
10. Pezzotti P, Phillips AN, Dorrucci M, et al. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1149 people with known dales of seroconversion. HIV Italian Seroconversion Study Group. BMJ 1996; 313:583-6.
11. Alcubes P, Schoenbaum EE, Klein RS. Correlates of the rate of decline of CD4' lymphocytes among injection drug users infected with the human immunodeficiency virus. Am J Epidemiol 1993; 137:989-1000.
12. Lyles CM, Margolick JB, Astemhorski J, et al. The influence of drug use patterns on the rate of CD4' lymphocyte decline among HIV-1-infected injecting drug users. Aids 1997; 11:1255-62.
13. Margolick JB. Munoz A, Vlahov D, et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection [see comments]. JAMA 1992;267:1631-6.
14. Markham RB, Wang W-C, Weisstein AE, et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci USA 1998;95:12568-73.
15. McNearney T, Hornickova Z, Markham R, et al. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Null Acad Sci USA 1992; 89:10247-51.
16. Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI. Human immunodeficiency virus type I evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994;68:6672-83.
17. Korber B, Wolinsky S, Haynes B, et al. HIV-1 intrapatient sequence diversity in the immunogenic V3 region, AIDS Res Hum Retroviruses 1992;8:1461-65.
18. Kuiken CL, Zwart G, Baan H, Coutinho RA, van den Hoek JA, Goudsmit J. Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci USA 1993; 90:9061-65.
19. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy [sec comments]. Science 1995;267:483-9.
20. Pang S, Shlesinger Y, Daar US, Moudgil T, Ho DO, Chen IS. Rapid generation of sequence variation during primary HIV-1 infection. AIDS 1992; 6:453-60.
21. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
22. Nowak M, Anderson R, Boerlijst M, Bonhoeffer S, May R, McMichael A. HIV-l evolution and disease progression. Science 1996;274:1008-11.
23. Bonhoeffer S, Holmes EC, Nowak MA. Causes of HIV diversity [letter]. Nature 1995:376:125.
24. Shankarappa R, Gupta P, Learn GH, Jr., et al. Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology 1998:241:251-9.
25. Wolinsky SM, Korber BT, Neumann AU, et al. Adaptive evolution of human immunodeficiency virus type I during the natural course of infection [see comments]. Science 1996:272:537-42.
26. Liu S-L, Schacker T, Musey L, et al. Divergent patterns of progression lo AIDS after infection from the same source: human immunodeficiency virus type I evolution and antiviral responses. J Virol 1997;71:4284-95.
27. Armstrong SJ, Mclnerncy TL, McLain L, et al. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J Gen Viral 1996;77:2931-41.
28. Groenink M, Andeweg AC, Fouchier RA, et al. Phenotype-associated env gene variation among eight related human immunodeficiency virus type I clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J Virol 1992:66:6175-80.
29. Cann AJ, Churchcr MJ, Boyd M, et al. The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol 1992:66:305-9.
30. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-l infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109:75-100.
31. McElrath K, Chitwood DD, Griffin PK, Comerford M. The consistency of self-reported HIV risk behavior among injection drug users. Am J Public Health 1994; 84:1965-70.
32. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993:88:517-26.
33. Liang KY, Zeger SL. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1993; 11:1685-1704.
34. Markham RB, Wang WC, Weisstein AE, et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci USA 1998;95:12568-73.
35. Munoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997;11:S69-76.
36. Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol 1998;83:133-8.
37. Bagasra O, Pomerantz RJ. Human immunodeficiency virus type 1 replication in peripheral blood mononuclcar cells in the presence of cocaine. J Infect Dis 1993; 168:1157-64.
38. Peterson PK, Gekker G, Schut R, Hu S, Balfour HH Jr, Chao CC. Enhancement of HIV-1 replication by opiates and cocaine: the cytokine connection. Adv Exp Med Biol 1993;335:181-8.
39. Peterson PK, Gekker O, Chao CC, et al. Cocaine amplifies HIV-1 replication in cytomegalovirus-stimulated peripheral blood mononuclear cell cocultures. J Immunol 1992;149:676-80.
40. Peterson PK, Gekker G, Chao CC, Schut R, Molitor TW, Balfour HH Jr. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures, Involvement of transforming growth factor-beta. J Immunol 1991;146:81-4.
41. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;80:1082-9.
42. Mudido PM, Georges D, Dorazio D, et al. Human immunodeficiency virus type I activation after blood transfusion. Transfusion 1996;36:860-5.
43. Killam KF, Jr., Chuang AJ. Chuang RY. Reduced sensitivity to AZT of SIV isolates from morphine treated rhesus monkeys. ProcWest Pharmacol Soc 1993:36:173-9.